JP2019508403A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508403A5
JP2019508403A5 JP2018540794A JP2018540794A JP2019508403A5 JP 2019508403 A5 JP2019508403 A5 JP 2019508403A5 JP 2018540794 A JP2018540794 A JP 2018540794A JP 2018540794 A JP2018540794 A JP 2018540794A JP 2019508403 A5 JP2019508403 A5 JP 2019508403A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
polynucleotide sequence
vaccine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540794A
Other languages
English (en)
Japanese (ja)
Other versions
JP7123800B2 (ja
JP2019508403A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/016557 external-priority patent/WO2017136758A1/en
Publication of JP2019508403A publication Critical patent/JP2019508403A/ja
Publication of JP2019508403A5 publication Critical patent/JP2019508403A5/ja
Application granted granted Critical
Publication of JP7123800B2 publication Critical patent/JP7123800B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540794A 2016-02-05 2017-02-03 がんのワクチン及びそれを用いた処置の方法 Active JP7123800B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291601P 2016-02-05 2016-02-05
US62/291,601 2016-02-05
PCT/US2017/016557 WO2017136758A1 (en) 2016-02-05 2017-02-03 Cancer vaccines and methods of treatment using the same

Publications (3)

Publication Number Publication Date
JP2019508403A JP2019508403A (ja) 2019-03-28
JP2019508403A5 true JP2019508403A5 (cg-RX-API-DMAC7.html) 2020-03-19
JP7123800B2 JP7123800B2 (ja) 2022-08-23

Family

ID=59500919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540794A Active JP7123800B2 (ja) 2016-02-05 2017-02-03 がんのワクチン及びそれを用いた処置の方法

Country Status (10)

Country Link
US (4) US11007255B2 (cg-RX-API-DMAC7.html)
EP (1) EP3411122A4 (cg-RX-API-DMAC7.html)
JP (1) JP7123800B2 (cg-RX-API-DMAC7.html)
KR (2) KR102742526B1 (cg-RX-API-DMAC7.html)
CN (2) CN108883312B (cg-RX-API-DMAC7.html)
AU (2) AU2017214656B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018015893A2 (cg-RX-API-DMAC7.html)
CA (1) CA3013718C (cg-RX-API-DMAC7.html)
MX (2) MX2018009506A (cg-RX-API-DMAC7.html)
WO (1) WO2017136758A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136758A1 (en) * 2016-02-05 2017-08-10 Inovio Pharmaceuticals, Inc. Cancer vaccines and methods of treatment using the same
CA3064890A1 (en) * 2017-05-26 2018-11-29 The Wistar Institute Of Anatomy And Biology Dtert vaccines and methods of treatment using the same
CN111511392A (zh) 2017-10-31 2020-08-07 潘塔希生物科学股份有限公司 用于治疗和/或预防肺癌的免疫治疗方法
BR112020011716A2 (pt) 2017-12-13 2020-11-17 Inovio Pharmaceuticals, Inc. molécula de ácido nucleico, seus usos, vetor, composição, proteína e vacina
PE20211755A1 (es) 2018-12-21 2021-09-07 Ionis Pharmaceuticals Inc Moduladores de la expresion de hsd17b13
WO2021259963A1 (en) 2020-06-23 2021-12-30 Pandora Endocrine Innovation B.V. Immunization against wnt4 for treatment and prophylaxis of breast cancer
US20250026818A1 (en) 2021-10-19 2025-01-23 Sciencemed Spóka z ograniczon odpowiedzialnoci Male contraception
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
WO2025146078A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
CA2153593C (en) 1993-01-26 2010-04-13 David B. Weiner Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6110161A (en) 1997-04-03 2000-08-29 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
BR9810369A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
WO2000002621A1 (en) 1998-07-13 2000-01-20 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
AU2003295366B2 (en) 2002-11-04 2011-11-24 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
DK2364769T3 (en) 2003-05-30 2016-04-11 Vgxi Inc Apparatus and methods for biomaterialeproduktion
KR102511874B1 (ko) 2006-07-28 2023-03-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
CN101522706B (zh) * 2006-10-12 2013-09-04 P.安杰莱蒂分子生物学研究所 端粒酶逆转录酶融合蛋白、编码它的核苷酸以及其用途
KR101421760B1 (ko) 2006-10-17 2014-07-22 브이지엑스 파머시우티컬즈, 인크. 포유류의 세포의 전기천공용 전기천공 장치 및 이의 사용 방법
CN105567672A (zh) 2007-05-23 2016-05-11 Vgxi公司 包含高浓度的生物活性分子的组合物及其制备工艺
US20140236070A1 (en) * 2011-07-29 2014-08-21 Kate Broderick Linear expression cassettes and uses thereof
EA201992251A1 (ru) * 2013-03-15 2020-05-08 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Противораковые вакцины и способы лечения с их применением
US10138488B2 (en) * 2013-03-28 2018-11-27 Invectys Cancer vaccine for dogs
US10398769B2 (en) * 2013-08-06 2019-09-03 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2017136758A1 (en) * 2016-02-05 2017-08-10 Inovio Pharmaceuticals, Inc. Cancer vaccines and methods of treatment using the same
CA3064890A1 (en) * 2017-05-26 2018-11-29 The Wistar Institute Of Anatomy And Biology Dtert vaccines and methods of treatment using the same

Similar Documents

Publication Publication Date Title
JP2019508403A5 (cg-RX-API-DMAC7.html)
US20230293608A1 (en) Oncolytic Vaccinia Virus
JP2017513502A5 (cg-RX-API-DMAC7.html)
JP2019193662A5 (cg-RX-API-DMAC7.html)
RU2016145464A (ru) Рекомбинантные вакцинные штаммы listeria и способы их получения
Cerullo et al. Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans
Marrero et al. Delivery of interleukin-15 to B16 melanoma by electroporation leads to tumor regression and long-term survival
WO2017205810A8 (en) Neoepitope vaccine compositions and methods of use thereof
PH12020500670A1 (en) Molecular adjuvant
JP2016516723A5 (cg-RX-API-DMAC7.html)
JP2016539946A5 (cg-RX-API-DMAC7.html)
JP2016505635A5 (cg-RX-API-DMAC7.html)
JP2016533749A5 (cg-RX-API-DMAC7.html)
WO2018228538A1 (zh) 重组单纯疱疹病毒及其制备方法和应用
RU2019107976A (ru) Композиция вакцины
MA40228A (fr) Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser
JP2016531927A5 (cg-RX-API-DMAC7.html)
RU2015103758A (ru) Днк-вакцина для применения у пациентов с раком поджелудочной железы
JP2014207903A5 (cg-RX-API-DMAC7.html)
JP2015506179A5 (cg-RX-API-DMAC7.html)
JP2019531293A5 (cg-RX-API-DMAC7.html)
JP2020511139A5 (cg-RX-API-DMAC7.html)
WO2011119925A3 (en) Synthetic herpes simplex viruses for treatment of cancers
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
RU2018123307A (ru) Вакцинация с использованием альфа3 домена mica/b для лечения рака